| scholarly article | Q13442814 |
| P50 | author | Dario Alessi | Q5222818 |
| Jinwei Zhang | Q47825457 | ||
| Xianming Deng | Q89024367 | ||
| Hwan Geun Choi | Q114430558 | ||
| Matthew P Patricelli | Q125308409 | ||
| Nathanael Gray | Q28112823 | ||
| P2093 | author name string | Zheng Zhao | |
| John M Hatcher | |||
| P2860 | cites work | Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. | Q46024777 |
| Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. | Q21135493 | ||
| Kinase activity of mutant LRRK2 mediates neuronal toxicity | Q24303603 | ||
| The selectivity of protein kinase inhibitors: a further update | Q24654622 | ||
| Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors | Q27663972 | ||
| Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
| Comprehensive analysis of kinase inhibitor selectivity | Q29616719 | ||
| Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening | Q33323340 | ||
| Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease | Q33812599 | ||
| Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models | Q33964804 | ||
| Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease | Q34112588 | ||
| Role of LRRK2 kinase dysfunction in Parkinson disease | Q34192817 | ||
| Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. | Q35780973 | ||
| Characterization of TAE684 as a potent LRRK2 kinase inhibitor | Q36208468 | ||
| (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. | Q36223954 | ||
| Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions | Q37225356 | ||
| LRRK2 and Parkinson disease | Q37748314 | ||
| On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies | Q37856642 | ||
| Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease | Q38009436 | ||
| Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. | Q40273125 | ||
| Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons | Q43120316 | ||
| A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. | Q43501182 | ||
| P433 | issue | 8 | |
| P921 | main subject | HG-10-102-01 | Q27225603 |
| P304 | page(s) | 658-662 | |
| P577 | publication date | 2012-06-18 | |
| P1433 | published in | ACS Medicinal Chemistry Letters | Q2819061 |
| P1476 | title | Brain Penetrant LRRK2 Inhibitor | |
| P478 | volume | 3 |
| Q28822157 | 'Up with the LRRK': a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagement |
| Q36402571 | 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening. |
| Q34764609 | A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases. |
| Q26746897 | Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease |
| Q38433725 | Cellular processes associated with LRRK2 function and dysfunction |
| Q42805112 | Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2. |
| Q52654614 | Current therapeutic molecules and targets in neurodegenerative diseases based on in silico drug design. |
| Q37732146 | Determining target engagement in living systems |
| Q41812724 | Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation |
| Q39776744 | Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor |
| Q35615188 | Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor |
| Q36682295 | Enantioselective synthesis of atropisomeric benzamides through peptide-catalyzed bromination. |
| Q34325540 | Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging |
| Q38225040 | Genetic, structural, and molecular insights into the function of ras of complex proteins domains. |
| Q27013695 | Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications |
| Q28551093 | Identification of a Tumor Specific, Active-Site Mutation in Casein Kinase 1α by Chemical Proteomics |
| Q40188432 | In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. |
| Q34527876 | Kinase drug discovery--what's next in the field? |
| Q38760031 | Kinase targets in CNS drug discovery. |
| Q48560989 | LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease |
| Q38620229 | LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand? |
| Q28078899 | LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives |
| Q54107836 | LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages. |
| Q58701452 | LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation |
| Q38253871 | LRRK2 pathobiology in Parkinson's disease |
| Q28602836 | LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias |
| Q42149865 | LRRK2 secretion in exosomes is regulated by 14-3-3. |
| Q35170220 | Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. |
| Q38977031 | Leucine-rich repeat kinase 2 and Parkinson's disease |
| Q38057769 | Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). |
| Q33920691 | Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy |
| Q41163700 | Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation |
| Q37214698 | Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors |
| Q21131229 | Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism |
| Q41828029 | Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1. |
| Q28119192 | Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases |
| Q51082148 | Regulation of LRRK2 by Phosphatases. |
| Q35472210 | Selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival |
| Q51082140 | Small-Molecule Inhibitors of LRRK2. |
| Q38213378 | Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation |
| Q92314123 | Synthesis and Preliminary Evaluation of [11 C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease |
| Q47142767 | Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. |
| Q39263032 | Targeting LRRK2 in Parkinson's disease: an update on recent developments |
| Q38160939 | Targeting leucine-rich repeat kinase 2 in Parkinson's disease |
| Q41374126 | The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. |
| Q64859135 | The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease |
| Q34552787 | Unique functional and structural properties of the LRRK2 protein ATP-binding pocket |
| Q39534317 | Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design? |
| Q38637928 | Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5 |
Search more.